CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study Drug-eluting balloons in coronary interventions: the quiet revolution? Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis

Original Research2008 Jun;57(6):1702-6.

JOURNAL:Diabetes. Article Link

Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes

Costacou T, Ferrell RE, Orchard TJ. Keywords: T1DM; haptoglobin genotype; haptoglobin 2/2 genotype;

FULL TEXT PDF